Roswell Park Cancer Institute — Biomedical Watch V2

Traitements7programmes

Essais2liés

Publications15liées

SourceDBlocale

Traitements

7

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
Anti-CD40 Agonist Monoclonal Antibody CDX-1140This phase II trial tests whether pembrolizumab combined with bevacizumab with or without agonist anti-CD40 CDX-1140 works to shrink tumors in patients with ovarian cancer that has come back (recurrent). Anti-CD40 CDX-1140 works by stimulating certain immune cells within the tumor and, when combined with other immunotherapy treatments, may increase antitumor antibody production. Immunotherapy with monoclonal antibodies, such as pembrolizumab and bevacizumab, may help the body's immune system, and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab and bevacizumab with anti-CD40 CDX-1140 may decrease symptoms, prolong survival, and improve quality of life in patients with ovarian cancer.	Cancer	Phase 2	Traitement symptomatique	United States	À vérifier
Incomplete Freund's AdjuvantThis phase I trial studies the side effects of survivin long peptide vaccine and how it works with the immune system in treating patients with neuroendocrine tumors that have spread to other parts of the body (metastatic). Tumor cells make proteins that are not usually produced by normal cells. The body sees these proteins as not belonging and sends white blood cells called T cells to attack the tumor cells that contain these proteins. By vaccinating with small pieces of these proteins called peptides, the immune system can be made to kill tumor cells. Giving survivin long peptide vaccine to patients who have survivin expression in their tumors may create an immune response in the blood that is directed against neuroendocrine tumors.	Cancer	Phase 1	Immunomodulation	United States	À vérifier
Octreotide AcetateThis phase I trial studies the side effects of survivin long peptide vaccine and how it works with the immune system in treating patients with neuroendocrine tumors that have spread to other parts of the body (metastatic). Tumor cells make proteins that are not usually produced by normal cells. The body sees these proteins as not belonging and sends white blood cells called T cells to attack the tumor cells that contain these proteins. By vaccinating with small pieces of these proteins called peptides, the immune system can be made to kill tumor cells. Giving survivin long peptide vaccine to patients who have survivin expression in their tumors may create an immune response in the blood that is directed against neuroendocrine tumors.	Cancer	Phase 1	Immunomodulation	United States	À vérifier
SargramostimThis phase I trial studies the side effects of survivin long peptide vaccine and how it works with the immune system in treating patients with neuroendocrine tumors that have spread to other parts of the body (metastatic). Tumor cells make proteins that are not usually produced by normal cells. The body sees these proteins as not belonging and sends white blood cells called T cells to attack the tumor cells that contain these proteins. By vaccinating with small pieces of these proteins called peptides, the immune system can be made to kill tumor cells. Giving survivin long peptide vaccine to patients who have survivin expression in their tumors may create an immune response in the blood that is directed against neuroendocrine tumors.	Cancer	Phase 1	Immunomodulation	United States	À vérifier
SVN53-67/M57-KLH Peptide VaccineThis phase I trial studies the side effects of survivin long peptide vaccine and how it works with the immune system in treating patients with neuroendocrine tumors that have spread to other parts of the body (metastatic). Tumor cells make proteins that are not usually produced by normal cells. The body sees these proteins as not belonging and sends white blood cells called T cells to attack the tumor cells that contain these proteins. By vaccinating with small pieces of these proteins called peptides, the immune system can be made to kill tumor cells. Giving survivin long peptide vaccine to patients who have survivin expression in their tumors may create an immune response in the blood that is directed against neuroendocrine tumors.	Cancer	Phase 1	Immunomodulation	United States	À vérifier
Incomplete Freund's AdjuvantThis phase I trial studies the side effects of survivin long peptide vaccine and how it works with the immune system in treating patients with neuroendocrine tumors that have spread to other parts of the body (metastatic). Tumor cells make proteins that are not usually produced by normal cells. The body sees these proteins as not belonging and sends white blood cells called T cells to attack the tumor cells that contain these proteins. By vaccinating with small pieces of these proteins called peptides, the immune system can be made to kill tumor cells. Giving survivin long peptide vaccine to patients who have survivin expression in their tumors may create an immune response in the blood that is directed against neuroendocrine tumors.	Cancer	Phase 1	Immunomodulation	United States	À vérifier
Anti-CD40 Agonist Monoclonal Antibody CDX-1140This phase II trial tests whether pembrolizumab combined with bevacizumab with or without agonist anti-CD40 CDX-1140 works to shrink tumors in patients with ovarian cancer that has come back (recurrent). Anti-CD40 CDX-1140 works by stimulating certain immune cells within the tumor and, when combined with other immunotherapy treatments, may increase antitumor antibody production. Immunotherapy with monoclonal antibodies, such as pembrolizumab and bevacizumab, may help the body's immune system, and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab and bevacizumab with anti-CD40 CDX-1140 may decrease symptoms, prolong survival, and improve quality of life in patients with ovarian cancer.	Cancer	Phase 2	Traitement symptomatique	United States	À vérifier

Essais cliniques

2

Molécule	Indication / population	Phase	NCT	Titre	Statut
Anti-CD40 Agonist Monoclonal Antibody CDX-1140	Cancer	Phase 2	NCT05231122	Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer	RECRUITING
Incomplete Freund's Adjuvant	Cancer	Phase 1	NCT03879694	Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors	COMPLETED

Publications

15

Molécule	Indication / population	Titre	Journal	Date
Sargramostim		Comorbidity of autoimmune diseases in patients with autoimmune pulmonary alveolar proteinosis.	Respiratory investigation
Sargramostim		Plain language summary: the evoke(+) studies of semaglutide for early Alzheimer's disease.	Neurodegenerative disease management
Incomplete Freund's Adjuvant		Is the temporomandibular joint affected by rheumatoid arthritis? A comparative investigation with knee arthritis in an experimental rat model.	Journal of anatomy
Incomplete Freund's Adjuvant		Comparative effects of topically applied diclofenac, ketoprofen, and piroxicam on interleukin-17, signal transducer and activator of transcription 3, and prostaglandin E2 levels in a rat model of collagen-induced arthritis.	Medicinski glasnik : official publication of the Medical Association of Zenica-Doboj Canton, Bosnia and Herzegovina
Sargramostim		Efficacy of anti-GD2 antibody immunotherapy with filgrastim and teceleukin versus standard treatment with sargramostim, aldesleukin and isotretinoin in children with high-risk neuroblastoma.	International journal of clinical oncology
Incomplete Freund's Adjuvant		Formation and preliminary characterization of mercury-reactive immunoglobulin Y antibodies in laying hens using HgCl-protein hapten conjugates.	Veterinary world
Octreotide Acetate		From pulmonary embolism to small intestinal neuroendocrine tumor: A new diagnostic perspective.	The Journal of international medical research
SVN53-67/M57-KLH Peptide Vaccine		Survivin as a potential mediator to support autoreactive cell survival in myasthenia gravis: a human and animal model study.	PloS one
SVN53-67/M57-KLH Peptide Vaccine		Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma.	Cancer immunology, immunotherapy : CII
Octreotide Acetate		Effect of octreotide-deoxycholate hydrophobic ion pairing solid dispersions on intestinal permeability to enhance octreotide absorption via increased lipophilicity and ASBT-mediated transport.	International journal of pharmaceutics
Octreotide Acetate		Developments in Pharmacotherapy for Acromegaly: Current and Emerging Approaches.	Drugs
Sargramostim		Diagnostic and Therapeutic Dilemmas in Recurrent Pulmonary Alveolar Proteinosis After Bilateral Lung Transplantation.	Respirology case reports
Sargramostim		A Marked Improvement in Mild but Progressive Autoimmune Pulmonary Alveolar Proteinosis Treated with Inhaled Granulocyte-Macrophage Colony-Stimulating Factor Therapy: A Case Report.	Internal medicine (Tokyo, Japan)
Incomplete Freund's Adjuvant		Effects of very early arthritis on pain, behavior, and hippocampal TNF/BDNF in rats.	Pediatric research
Incomplete Freund's Adjuvant		Antibody response induced by structural proteins from as potential adjuvants in experimental immunisation models.	Frontiers in microbiology